Anika Announces Third Quarter 2024 Results Conference Call Date
- BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 financial results before the opening of the market on Thursday, October 31, 2024, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
- 10/17/2024
|
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BEDFORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 2024, Anika granted non-statutory stock options (āOptionsā) covering an aggregate of 6,350 shares of common stock at a per share exercise price of $24.27, which equaled the closing price of common stock on the Nasdaq Global Select Market (āClosing Priceā) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing RuleĀ 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.
- 10/04/2024
|
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BEDFORD, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 3, 2024, Anika granted non-statutory stock options (āOptionsā) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.15, which equaled the closing price of common stock on the Nasdaq Global Select Market (āClosing Priceā) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing RuleĀ 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.
- 09/09/2024
|
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BEDFORD, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on August 1, 2024, Anika granted non-statutory stock options (āOptionsā) covering an aggregate of 8,850 shares of common stock at a per share exercise price of $26.29, which equaled the closing price of common stock on the Nasdaq Global Select Market (āClosing Priceā) on the grant date, to two newly hired non-executive employees. The grants were made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing RuleĀ 5635(c)(4), were made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.
- 08/15/2024
|
Anika Therapeutics, Inc (ANIK) Q2 2024 Earnings Call Transcript
- Anika Therapeutics, Inc (NASDAQ:ANIK ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations Cheryl Blanchard - President and Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Company Harrison Parsons - Stephens Mike Petusky - Barrington Research Operator Good afternoon, ladies and gentlemen, and welcome to Anika's Second Quarter 2024 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Namaroff, Vice President, Investor Relations, ESG and Corp. Communications.
- 08/11/2024
|
Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates
- Anika Therapeutics (ANIK) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.19 per share a year ago.
- 08/08/2024
|
Anika Reports Second Quarter 2024 Financial Results
- Expanded Regenerative Solutions portfolio with full market release of the Integrityā¢ Ā Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand
- 08/08/2024
|
Anika to Participate in the Sidoti Virtual Investor Conference
- BEDFORD, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Thursday, August 15, 2024. Anika will host a virtual presentation with Q&A starting at 11:30am ET.
- 08/05/2024
|
Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024
- BEDFORD, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2024 financial results after the close of the market on Thursday, August 8, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
- 07/25/2024
|
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BEDFORD, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on July 1, 2024, Anika granted non-statutory stock options (āOptionsā) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.85, which equaled the closing price of common stock on the Nasdaq Global Select Market (āClosing Priceā) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing RuleĀ 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.
- 07/16/2024
|
Anika Announces Full Market Release of the Integrityā¢ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs
- Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolio
- 07/11/2024
|
Orthopedic Regenerative Surgical Products Market Size to Reach USD 6.6 Billion By 2033, at 4.4 CAGR: Insights by Dimension Market Research
- Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments
- 07/01/2024
|
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BEDFORD, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on June 3, 2024, Anika granted: (i) non-statutory stock options (āOptionsā) covering 96,525 shares of common stock at a per share exercise price of $29.35, which equaled 110% of the closing price of common stock on the Nasdaq Global Select Market (āClosing Priceā) on the grant date, and (ii) restricted stock units (āRSUsā) covering 38,520 shares of common stock, to Stephen Griffin, the Company's recently appointed Executive Vice President, Chief Financial Officer and Treasurer. The grants were made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing RuleĀ 5635(c)(4), were made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.
- 06/07/2024
|
Anika Enters into Cooperation Agreement with Caligan Partners
- Appoints Joseph Capper and William Jellison to Board of Directors Announces New $40 Million Share Repurchase Program
- 05/28/2024
|
Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript
- Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2024 Earnings Conference Call May 8, 2024 5:30 PM ET Company Participants Mark Namaroff - Vice President of Investor Relations, ESG and Corporate Communications Cheryl Blanchard - President and Chief Executive Officer Michael Levitz - Executive Vice President and Chief Financial Officer Conference Call Participants George Sellers - Stephens Inc. James Sidoti - Sidoti & Company, LLC Mike Petusky - Barrington Research Operator Good evening, ladies and gentlemen, and welcome to Anika's First Quarter 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.
- 05/08/2024
|
Anika Announces CFO Transition
- Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024 Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024
- 05/08/2024
|
Anika Reports First Quarter 2024 Financial Results
- Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the midpoint BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2024.
- 05/08/2024
|
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on May 1, 2024, Anika granted non-statutory stock options (āOptionsā) covering an aggregate of 3,800 shares of common stock at a per share exercise price of $26.49, which equaled the closing price of common stock on the Nasdaq Global Select Market (āClosing Priceā) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing RuleĀ 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.
- 05/03/2024
|
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
- BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2024 financial results after the close of the market on Wednesday, May 8, 2024 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights.
- 04/18/2024
|
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- BEDFORD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024. Anika will host a virtual presentation with Q&A starting at 2:15pm ET.
- 04/02/2024
|
Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript
- Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript
- 03/13/2024
|
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
- Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reduction initiatives providing annualized savings of approximately $10 million Anika positioned to generate adjusted EBITDA1 of $25 to $30 million in 2024, up over 75% at the midpoint, representing an adjusted EBITDA1 margin of at least 15% BEDFORD, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its fourth quarter and full year ended December 31, 2023.
- 03/13/2024
|
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BEDFORD, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on March 1, 2024, Anika granted non-statutory stock options (āOptionsā) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.14, which equaled the closing price of common stock on the Nasdaq Global Select Market (āClosing Priceā) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing RuleĀ 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.
- 03/08/2024
|
Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
- BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2023 financial results after the close of the market on Wednesday, March 13, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
- 02/27/2024
|
Anika Highlights Its Recently Launched Integrityā¢ Implant System and RevoMotionā¢ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting
- Announcing the limited market release of X-Twistā¢ Fixation System with biocomposite suture anchor for rotator cuff and other soft tissue repair at AAOS
- 02/13/2024
|
New Strong Buy Stocks for December 14th
- MUSA, AVTX, ANIK, CARG and WES have been added to the Zacks Rank #1 (Strong Buy) List on December 14, 2023.
- 12/14/2023
|
Anika Announces First Surgeries Performed using the Integrityā¢ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release
- Integrity marks Anika's entrance into the fast-growing $150 million+2 U.S. rotator cuff augmentation market and expansion of its proprietary hyaluronic acid (HA) regenerative portfolio
- 11/28/2023
|
Anika to Participate in Upcoming Investor Conferences
- BEDFORD, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr.Ā Cheryl Blanchard, President and Chief Executive Officer andĀ Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will be participating at the following investor conferences:
- 11/07/2023
|
Anika Therapeutics, Inc. (ANIK) Q3 2023 Earnings Call Transcript
- Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2023 Earnings Conference Call November 2, 2023 5:30 PM ET Company Participants Mark Namaroff - Vice President Investor Relations, ESG & Corporate Communications Cheryl Blanchard - President & Chief Executive Officer Mike Levitz - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Mike Petusky - Barrington Research George Sellers - Stephens Inc Jim Sidoti - Sidoti & Company Operator Good evening, ladies and gentlemen, and welcome to Anika's Third Quarter 2023 Earnings Conference Call. All participants' will be in a listen-only mode.
- 11/03/2023
|
Anika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business
- Revenue Growth Exceeded Expectations in the Third Quarter and Year-To-Date, with Joint Preservation and Restoration up 14% and 10% and OA Pain Management up 2% and 11%, Respectively
- 11/02/2023
|
Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023
- BEDFORD, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2023 financial results after the close of the market on Thursday, November 2, 2023 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights.
- 10/10/2023
|
Protect Your Portfolio From Volatility With 3 Low-Beta Picks
- At this stage, it is prudent to invest in low-beta stocks with a favorable Zacks Rank like ALC, RDY and ANIK, as these will be less volatile than the broader market.
- 09/29/2023
|
Anika Announces the Full Market Release of the RevoMotionā¢ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual Meeting
- RevoMotion Reverse Shoulder Arthroplasty System significantly expands Anika's shoulder arthroplasty portfolio and provides a bone conserving and innovative solution in the $1 billion1 U.S. reverse shoulder market
- 09/19/2023
|
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BEDFORD, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 5, 2023, Anika granted restricted stock units ( āRSUsā) covering 10,000 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing RuleĀ 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.
- 09/15/2023
|
Down -20.42% in 4 Weeks, Here's Why You Should You Buy the Dip in Anika (ANIK)
- The heavy selling pressure might have exhausted for Anika (ANIK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 09/01/2023
|
All You Need to Know About Anika (ANIK) Rating Upgrade to Buy
- Anika (ANIK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 08/31/2023
|
Anika (ANIK) Loses -19.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Anika (ANIK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 08/31/2023
|
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates
- Anika Therapeutics (ANIK) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.20 per share a year ago.
- 08/08/2023
|
Anika to Issue Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
- BEDFORD, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2023 financial results after the close of the market on Tuesday, August 8, 2023 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
- 07/20/2023
|
Anika Therapeutics Inc. (ANIK) Q1 2023 Earnings Call Transcript
- Anika Therapeutics Inc. (NASDAQ:ANIK ) Q1 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Mark Namaroff - Executive Director of IR & Corporate Communications Cheryl Blanchard - President, CEO & Director Michael Levitz - Executive VP, CFO & Treasurer Conference Call Participants Harrison Parsons - Stephens Mike Petusky - Barrington Research Jim Sidoti - Sidoti Operator Good afternoon, ladies and gentlemen, and welcome to Anika's First Quarter 2023 Earnings Conference Call. [Operator Instructions] This call is being recorded on Tuesday, May 9, 2023.
- 05/13/2023
|
Anika Therapeutics (ANIK) Reports Q1 Loss, Tops Revenue Estimates
- Anika Therapeutics (ANIK) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.20 per share a year ago.
- 05/09/2023
|
Anika to Issue First Quarter 2023 Financial Results on Tuesday, May 9, 2023
- BEDFORD, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2023 financial results after the close of the market on Tuesday, May 9, 2023 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
- 04/19/2023
|
Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue Estimates
- Anika (ANIK) delivered earnings and revenue surprises of -54.55% and 3.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/06/2023
|
Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year?
- Here is how Anika Therapeutics (ANIK) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
- 01/17/2023
|
7 Stocks to Buy Before the Market Starts to Soar in 2023
- With Americans being an optimistic bunch, the general assumption that the equities sector will rise following the ugly year in 2022 fundamentally bolsters several stocks to buy. However, it's important to be selective.
- 11/10/2022
|
Anika Therapeutics (ANIK) Reports Q3 Loss, Tops Revenue Estimates
- Anika (ANIK) delivered earnings and revenue surprises of -20.83% and 10.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/08/2022
|
Anika Therapeutics, Inc. (ANIK) Q3 2022 Earnings Call Transcript
- Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2022 Results Conference Call November 8, 2022 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Dr. Cheryl Blanchard - President and Chief Executive Officer Mike Levitz - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants George Sellers - Stephens Incorporated Mike Petusky - Barrington Research Jim Sidoti - Sidoti & Company Operator Good evening, ladies and gentlemen, and welcome to Anika's Third Quarter 2022 Earnings Conference Call. Today's conference is being recorded.
- 11/08/2022
|
Anika to Issue Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
- BEDFORD, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2022 financial results after the close of the market on Tuesday, November 8, 2022 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
- 10/25/2022
|
Anika Therapeutics Inc. (ANIK) CEO Cheryl Blanchard on Q2 2022 Results - Earnings Call Transcript
- Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Cheryl Blanchard - President and Chief Executive Officer Michael Levitz - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants James Sidoti - Sidoti & Company Michael Petusky - Barrington Research Operator Good evening, ladies and gentlemen, and welcome to Anika's Second Quarter 2022 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Namaroff, Vice President of Investor Relations, ESG and Corporate Communications.
- 08/06/2022
|
Anika to Issue Second Quarter 2022 Financial Results on Wednesday, August 3, 2022
- BEDFORD, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2022 financial results after the close of the market on Wednesday, August 3, 2022 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
- 07/12/2022
|
Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
- BEDFORD, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the Sidoti Small Cap Virtual Investor Conference on Wednesday, June 15, 2022. Anika will host a virtual presentation with Q&A starting at 11:30am ET.
- 06/10/2022
|
Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q1 2022 Results - Earnings Call Transcript
- Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Mark Namaroff - VP, IR, ESG and Corporate Communications Cheryl Blanchard - President and CEO Mike Levitz - EVP, CFO and Treasurer Conference Call Participants Chris Cooley - Stephens Jim Sidoti - Sidoti & Company Operator Good evening, ladies and gentlemen, and welcome to Anika's First Quarter 2022 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Namaroff, Vice President, Investor Relations, ESG and Corporate Communications.
- 05/07/2022
|
New Strong Sell Stocks for April 26th
- ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022
- 04/26/2022
|
New Strong Sell Stocks for April 19th
- ANIK, APP, and ARCE have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2022.
- 04/19/2022
|
Anika to Issue First Quarter 2022 Financial Results on Thursday, May 5, 2022
- BEDFORD, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2022 financial results after the close of the market on Thursday, May 5, 2022 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
- 04/07/2022
|
New Strong Sell Stocks for April 7th
- AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.
- 04/07/2022
|
New Strong Sell Stocks for April 4th
- AKU, ANIK, and AY have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2022.
- 04/04/2022
|
New Strong Sell Stocks for March 28th
- ALIM, ANIK, and APPF have been added to the Zacks Rank #5 (Strong Sell) List on March 28, 2022
- 03/28/2022
|
New Strong Sell Stocks for March 21st
- ARAY, AKU, and ANIK have been added to the Zacks Rank #5 (Strong Sell) List on March 21, 2022
- 03/21/2022
|
Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity
- Anika Therapeutics' share price is being punished by the market owing to some possibly over-ambitious growth projections made in June last year.
- 03/11/2022
|
Anika Therapeutics Inc's (ANIK) CEO Cheryl Blanchard on Q4 2021 Results - Earnings Call Transcript
- Anika Therapeutics Inc's (ANIK) CEO Cheryl Blanchard on Q4 2021 Results - Earnings Call Transcript
- 03/08/2022
|
Anika to Issue Fourth Quarter and Year-End 2021 Financial Results on Tuesday, March 8, 2022
- BEDFORD, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2021 financial results after the close of the market on Tuesday, March 8, 2022 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
- 02/08/2022
|
Anika to Participate in Upcoming Investor Conferences
- BEDFORD, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will be participating at the following investor conferences:
- 11/18/2021
|
Anika Therapeutics' (ANIK) CEO Cheryl Blanchard on Q3 2021 Results - Earnings Call Transcript
- Anika Therapeutics' (ANIK) CEO Cheryl Blanchard on Q3 2021 Results - Earnings Call Transcript
- 11/05/2021
|
Anika Launches the WristMotionĀ® Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annual Meeting
- Designed to preserve natural motion and maximize stability, the WristMotionĀ® Total Wrist Arthroplasty System provides an advanced solution for wrist arthritis and an alternative to wrist fusion Designed to preserve natural motion and maximize stability, the WristMotionĀ® Total Wrist Arthroplasty System provides an advanced solution for wrist arthritis and an alternative to wrist fusion
- 09/30/2021
|
Anika to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
- BEDFORD, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 15, 2021 at 2:00 p.m. ET.
- 09/07/2021
|
Anika to Debut Joint Preservation Portfolio at the 2021 AAOS Annual Meeting
- Anika, now combined with Arthrosurface and Parcus Medical, meets the evolving unmet needs of surgeons in the global joint preservation market Anika, now combined with Arthrosurface and Parcus Medical, meets the evolving unmet needs of surgeons in the global joint preservation market
- 09/01/2021
|
Anika Therapeutics' (ANIK) CEO Cheryl Blanchard on Q2 2021 Results - Earnings Call Transcript
- Anika Therapeutics' (ANIK) CEO Cheryl Blanchard on Q2 2021 Results - Earnings Call Transcript
- 08/07/2021
|
Anika to Issue Second Quarter 2021 Financial Results on Thursday, August 5, 2021
- BEDFORD, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2021 financial results after the close of the market on Thursday, August 5, 2021 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
- 07/19/2021
|
Anika to Host its 2021 Virtual Investor Day on June 3, 2021
- BEDFORD, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to host its 2021 Virtual Investor Day on Thursday, June 3, 2021 beginning at 9:00am EDT.
- 05/13/2021
|
Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q1 2021 Results - Earnings Call Transcript
- Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q1 2021 Results - Earnings Call Transcript
- 05/09/2021
|
Anika Therapeutics (ANIK) Surpasses Q1 Earnings and Revenue Estimates
- Anika (ANIK) delivered earnings and revenue surprises of 225.00% and 5.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/06/2021
|
Anika to Issue First Quarter 2021 Financial Results on Thursday, May 6, 2021
- BEDFORD, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2021 financial results after the close of the market on Thursday, May 6, 2021 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
- 04/15/2021
|
Anika to Participate in the 20th Annual Needham Virtual Healthcare Conference
- BEDFORD, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will present at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 3:45 p.m. ET.
- 04/05/2021
|
Anika to Participate in the Sidoti Spring Virtual Investor Conference
- BEDFORD, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will present at the Sidoti Spring Virtual Investor Conference on Thursday, March 25, 2021 at 8:30 a.m. ET.
- 03/11/2021
|
Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q4 2020 Results - Earnings Call Transcript
- Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q4 2020 Results - Earnings Call Transcript
- 03/04/2021
|
Anika Therapeutics (ANIK) Reports Q4 Loss, Lags Revenue Estimates
- Anika (ANIK) delivered earnings and revenue surprises of -1000.00% and -2.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/04/2021
|
Recap: Anika Therapeutics Q4 Earnings
- Shares of Anika Therapeutics (NASDAQ:ANIK) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 72.09% year over year to $0.12, which beat the estimate of ($0.01).
- 03/04/2021
|
Anika to Issue Fourth Quarter and Year-End 2020 Financial ResultsĀ on Thursday, March 4, 2021
- BEDFORD, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company plans to issue its fourth quarter and year-end 2020 financial results after the close of the market on Thursday, MarchĀ 4, 2021 and hold its investor conference call and webcast on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
- 02/09/2021
|
Keep These 4 Toxic Stocks Away From Your Portfolio
- Just like selecting good and undervalued stocks on a regular basis can make you rich, identifying and proactively getting rid of toxic stocks is also crucial to maximizing portfolio returns.
- 01/04/2021
|
Anika Therapeutics (ANIK) Surges: Stock Moves 6.6% Higher
- Anika Therapeutics (ANIK) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- 12/21/2020
|
Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q3 2020 Results - Earnings Call Transcript
- Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q3 2020 Results - Earnings Call Transcript
- 11/04/2020
|
Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q3 2020 Results - Quick Version Earnings Call Transcript
- Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q3 2020 Results - Quick Version Earnings Call Transcript
- 11/04/2020
|
Anika Reports Third-Quarter 2020 Financial Results
- Revenue Increased 7% Year-over-Year to $ 31.7 Million Repaid $25 M illion of Outstanding Credit Facility Continued Expansion of Joint Preservation Product Portfolio
- 11/04/2020
|
La contrarreloj que decidirĆ” el Tour, en directo: Lure - La Planche des Belles Filles- Tour de Francia
- Toda la informaciĆ³n actualizada al minuto por nuestros comentaristas La contrarreloj que decidirĆ” el Tour, en directo: Lure - La Planche des Belles Filles...
- 09/24/2020
|
Historic Annapolis' Popular Virtual Lecture Series Continues
- Contact: Carrie Kiewitt
- 09/22/2020
|
InMode Sets 2020 Stretch Goal To Exceed 2019 Revenue
- InMode went public in August, 2019, raising $70 million. The firm sells medical aesthetic technologies in the U.S.
- 08/16/2020
|
Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
- Most readers would already be aware that Anika Therapeutics' (NASDAQ:ANIK) stock increased significantly by 16% over...
- 08/10/2020
|
Anika Therapeutics, Inc. (NASDAQ:ANIK) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
- Anika Therapeutics' (NASDAQ:ANIK) stock is up by a considerable 16% over the past three months. However, we decided to...
- 08/10/2020
|
Insights on the Global Osteoarthritis Therapeutics Market 2020-2024 |COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio
- The Global Osteoarthritis Therapeutics Market will grow by USD 2.99 bn during 2020-2024
- 08/07/2020
|
Anika Appoints Michael Levitz as Chief Financial Officer
- Seasoned financial executive brings broad medical device industry experience andĀ track record of value creationBEDFORD, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, today announced the appointment of Michael Levitz as Executive Vice President, Chief Financial Officer and Treasurer, starting August 10, 2020. Mr. Levitz brings over 20 years of public company financial experience to Anika and has helped deliver significant increases in enterprise value and operating performance at several medical device companies. He succeeds Sylvia Cheung, who will continue with the Company in an advisory capacity for a period following the succession effective date to assist with a smooth transition. āAnika is delighted to welcome Mike to our leadership team during this pivotal time of momentum and growth for the Company,ā said Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer of Anika. āHis extensive experience building, developing, and retaining high-performing teams during significant periods of growth and transformation will be invaluable as we continue to integrate the acquisitions of Parcus Medical and Arthrosurface, leverage our expanded global commercial reach, and advance our strategic growth plan.āāAnika is at an exciting stage of its corporate evolution, with a strong financial foundation and a robust and growing early intervention orthopedic product portfolio and pipeline,ā said Mr. Levitz. āI look forward to contributing to the Companyās culture of financial discipline and investment in innovation to accelerate growth and value creation for shareholders.āPrior to joining Anika, Mr. Levitz served as Senior Vice President, Chief Financial Officer and Treasurer of Insulet Corporation, a global innovative medical device and drug delivery company. Prior to Insulet, from 2009 to 2015 he was the Senior Vice President, Chief Financial Officer and Treasurer of Analogic Corporation, a global provider of medical guidance, diagnostic imaging and threat detection equipment. Previously, during his seven years with Hologic, Inc. and Cytyc Corporation (which merged with Hologic in October 2007), Mr. Levitz served in various capacities including Vice President and Corporate Controller. Mr. Levitz began his career in the high technology audit practice at Arthur Andersen. Mr. Levitz earned his Bachelor of Arts in Business Economics, with emphasis in Accounting, from the University of California Santa Barbara and is a certified public accountant. In 2011, he was a finalist for the Boston Business Journal's Chief Financial Officer of the Year award.About Anika Therapeutics, Inc.Anika Therapeutics, Inc.Ā (NASDAQ: ANIK), is a global, integrated joint preservation, restoration and regenerative solutions company based in Bedford, Massachusetts. Anika is committed to delivering products along the orthopedic early intervention continuum of care to improve the lives of patients, with a focus on osteoarthritis pain management, sports medicine and joint preservation, restoration and regeneration. The Company has close to three decades of global expertise commercializing innovative products across the orthopedic early intervention continuum of care. For more information about Anika, please visit www.anikatherapeutics.com. For Investor Inquiries: Anika Therapeutics, Inc. Kristen Galfetti, 781-457-9000 Executive Director, Investor Relations investorrelations@anikatherapeutics.com Ā For Media Inquiries: W2O Group Rachel Girard, 617-379-6760 Ā rgirard@w2ogroup.com
- 08/05/2020
|
ANIK or ALKS: Which Is the Better Value Stock Right Now?
- ANIK vs. ALKS: Which Stock Is the Better Value Option?
- 08/05/2020
|
Did Hedge Funds Make The Right Call On Anika Therapeutics, Inc. (ANIK) ?
- How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of [ā¦]
- 08/04/2020
|
Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q2 2020 Results - Earnings Call Transcript
- Anika Therapeutics, Inc. (NASDAQ:ANIK) Q2 2020 Earnings Conference Call July 30, 2020 5:00 PM ET Company Participants Kristen Galfetti - Investor Relations Cheryl Blanchard - President and Chief Executive Officer Sylvia Cheung - Chief Financial Officer Conference Call Participants Jim Sidoti - Sidoti & Company, LLC Michael Petusky - Barrington Research Associates, Inc.
- 08/02/2020
|
Anika Therapeutics: After A Stormy Period, Orthopedic Specialist Looks Set Fair
- Anika is an exciting play in the orthopedic space. The company provides joint preservation, regenerative therapies and sports medicine.
- 07/31/2020
|
Anika Therapeutics, Inc. 2020 Q2 - Results - Earnings Call Presentation
- The following slide deck was published by Anika Therapeutics, Inc. in conjunction with their 2020 Q2 earnings call..
- 07/31/2020
|
Anika Therapeutics Inc (ANIK) Q2 2020 Earnings Call Transcript
- With me today on the call is Dr. Cheryl Blanchard, President and Chief Executive Officer; and Sylvia Cheung, Chief Financial Officer of Anika. During today's call, Cheryl and Sylvia will review Anika's second quarter 2020 financial results and key business highlights, which are summarized in our earnings release today.
- 07/30/2020
|
Anika Therapeutics (ANIK) Q2 Earnings and Revenues Surpass Estimates
- Anika (ANIK) delivered earnings and revenue surprises of 142.86% and 83.37%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 07/30/2020
|
Anika Reports Second Quarter 2020 Financial Results
- Increased Total Revenue 1% Year-over-Year to $30.7 Million Accelerated the Commercial Integration of Parcus Medical and Arthrosurface Organizations Launching Seven FDA-Cleared Orthopedic and Sports Medicine Products Through Q3 2020BEDFORD, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, today reported financial results for the second quarter ended June 30, 2020, and provided an update on its business progress in the period.āAnikaās recent strategic transformation has provided commercial diversity and generated top-line revenue growth year-over-year for the quarter, despite the COVID-19 pandemic impact,ā said Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer of Anika Therapeutics. āThe Company also made continued progress as a customer-centric company focused on the early intervention orthopedic continuum of care, including forming a new leadership team and a consolidated commercial structure as part of the integration of Parcus Medical and Arthrosurface. We are expanding our product portfolio with several innovations that address the needs of orthopedic and sports medicine surgeons with seven new product launches through the third quarter of 2020. The health and safety of our employees, the customers we serve and all of the patients they treat around the world remains our top priority, while we continue to take actions to control our costs and maintain our strong balance sheet during the COVID-19 pandemic.āSecond Quarter Financial ResultsĀ * Total revenue for the second quarter of 2020 increased 1% year-over-year to $30.7 million, compared to $30.4 million for the second quarter of 2019. The increase in total revenue was due primarily to new Orthopedic Joint Preservation and Restoration revenue, which resulted from the acquisitions of Parcus Medical and Arthrosurface in the first quarter of 2020, partially off-set by lower Joint Pain Management revenue as a result of the COVID environment. * Cost of product revenue, research and development expenses and selling, general and administrative expenses for the second quarter of 2020 were $36.0 million, compared to $18.5 million for the second quarter of 2019. The increase was due primarily to higher cost of product revenue, selling and marketing expenses related to the Companyās newly acquired sales infrastructure, acquisition related amortization expenses and product rationalization charges associated with certain non-core legacy products. Acquisition related non-cash expenses and product rationalization non-cash charges during the quarter totaled $6.9 million. * Included in total operating expenses for the second quarter of 2020 was a $4.2 million increase in fair value related to acquisition contingent consideration liabilities, recorded as a non-cash expense, as a result of the estimated improved performance of the recently acquired companies following the easing of COVID restrictions in the U.S. * Net loss for the second quarter of 2020 was $7.7 million, or $0.54 loss per diluted share, compared to net income of $9.4 million, or $0.67 per diluted share, for the second quarter of 2019. Adjusted net income (see description below) for the second quarter of 2020 was $1.2 million, or $0.09 per diluted share. * Adjusted EBITDA (see description below) for the second quarter of 2020 was $5.6 million, compared to $14.8 million for the second quarter of 2019. The year-over-year decrease was due primarily to increases in cost of product revenue and related revenue mix and selling and marketing expenses. * Cash, cash equivalents and investments were $144.4 million as of June 30, 2020, compared to $184.9 million as of December 31, 2019. The decrease in cash, cash equivalents and investments was due to $93.0 million of upfront payments for the acquisitions of Parcus Medical and Arthrosurface, offset by the $50.0 million drawdown on the Companyās existing credit facility.Ā Ā Ā Ā Ā Ā Ā Recent Business Highlights * Augmented the leadership team to maximize talent utilization and efficiency, as well as drive performance, including the appointments of: āĀ Bart Bracy, former Senior Vice President and Co-Founder of Parcus Medical, as Vice President of Sales and Marketing for the Americas region; āĀ Steven Ek, former President and Chief Executive Officer of Arthrosurface, as Vice President of Research and Development; āĀ Mark Brunsvold, former President and Co-Founder of Parcus Medical, as President of Sports Medicine; and āĀ James Chase as Senior Vice President of International Sales and Marketing, with expanded responsibility for Anikaās operations in Padua, Italy. * Completed the integration of the Companyās U.S. commercial organization, which includes 35 sales professionals in addition to shared sales operations and marketing functions. * Expanded the TACTOSET franchise, Anikaās surgically delivered regenerative therapy for bone repair procedures focused on treating insufficiency fractures, to include a small bone cannula set enabling improved and more accurate access in small joints and extremities. * Completed prelaunch activities for six sports medicine surgical devices and instruments, which recently received U.S. Food and Drug Administration clearance. The new products are used in procedures ranging from rotator cuff repair to arthroscopic knee repairs and the treatment of arthritis damage in the hand and wrist. The products will be commercialized through Anikaās recently expanded sales and marketing team through the third quarter of 2020. * Continued international expansion of the Companyās joint pain management business through the launch and first sales of CINGAL in Australia, as well as the receipt of visocsupplement product approvals in Finland and Serbia.Non-GAAP Information Adjusted EBITDATo supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company reports adjusted EBITDA, which is a non-GAAP financial measure and should not be considered an alternative to net income or other measurements under GAAP. The Company believes that adjusted EBITDA provides additional useful information to investors in their assessment of its operating performance as it is a metric routinely used by management to evaluate the Companyās performance. Adjusted EBITDA is not calculated identically by all companies, and therefore the Companyās measurements of adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. In 2020, adjusted EBITDA is defined by the Company as GAAP net income excluding depreciation and amortization, interest and other income (expense), income taxes, stock-based compensation expense, acquisition related costs, non-cash charges related to goodwill impairment and changes in the fair value of contingent consideration associated with the Companyās recent acquisitions as a result of the COVID-19 pandemic, and product rationalization charges associated with certain non-core legacy products. Acquisition related expenses are those that the Company would not have incurred except as a direct result of acquisition transactions. Acquisition related expenses consist of investment banking, legal, accounting, and other professional and related expenses associated with acquisition transactions, as well as amortization of inventory step-up and identified assets associated with purchase accounting for the transactions. Acquisition related expenses are being reported and utilized in the Companyās calculation of adjusted EBITDA in order to facilitate comparison to the Companyās past performance. As a result of the impact of COVID-19, the Company is also excluding the impacts of goodwill impairment charges and changes in the fair value in contingent consideration associated with the recent acquisition transactions. Product rationalization charges being excluded relate to certain non-core legacy assets as result of managing the Companyās financial position in light of its recent acquisitions, the impact of COVID-19 and changing regulatory requirements. These non-cash charges are related to current product inventory and fixed and intangible assets. The Company is reporting this financial measure to the Board of Directors in order to facilitate an appropriate assessment of the Companyās performance and the impact of the COVID-19 pandemic. A reconciliation of adjusted EBITDA to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, is shown in the table below for the three- and six-month periods ended June 30, 2020 and 2019.Ā Ā Ā Ā Ā Ā Ā Ā Ā Anika Therapeutics, Inc.
- 07/30/2020
|
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Adamis Pharmaceuticals Corp (NASDAQ: ADMP)
Annexon...
- 07/30/2020
|
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
- Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
- 07/26/2020
|
Earnings Preview: Anika Therapeutics (ANIK) Q2 Earnings Expected to Decline
- Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/23/2020
|
Anika To Launch Six FDA-Cleared Sports Medicine and Extremities Products in Third Quarter of 2020
- BEDFORD, Mass., July 20, 2020 -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products.
- 07/20/2020
|
Contrasting STRATA Skin Sciences (NASDAQ:SSKN) and Anika Therapeutics (NASDAQ:ANIK)
- STRATA Skin Sciences (NASDAQ:SSKN) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership. Profitability This table compares STRATA Skin Sciences and Anika Therapeuticsā net margins, return on [ā¦]
- 07/18/2020
|
Anika to Issue Second Quarter 2020 Financial Results and Business Highlights on Thursday, July 30
- BEDFORD, Mass., July 16, 2020 -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products.
- 07/16/2020
|
Analysts Estimate Anika Therapeutics (ANIK) to Report a Decline in Earnings: What to Look Out for
- Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/15/2020
|
Anika Therapeutics Inc (NASDAQ:ANIK) Shares Bought by Royal Bank of Canada
- Royal Bank of Canada grew its holdings in Anika Therapeutics Inc (NASDAQ:ANIK) by 5.4% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 48,460 shares of the biotechnology companyās stock after buying an additional 2,483 shares during the period. Royal Bank of Canada owned 0.34% of Anika Therapeutics [ā¦]
- 07/13/2020
|
6 Meridian Lowers Holdings in Anika Therapeutics Inc (NASDAQ:ANIK)
- 6 Meridian lowered its stake in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 62.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,691 shares of the biotechnology companyās stock after selling 9,460 shares during the period. 6 Meridianās [ā¦]
- 07/12/2020
|
Worldwide Adhesion Barriers Market to 2027 - Impact of COVID-19 on the Industry - ResearchAndMarkets.com
|
BidaskClub Upgrades Anika Therapeutics (NASDAQ:ANIK) to Buy
- Anika Therapeutics (NASDAQ:ANIK) was upgraded by stock analysts at BidaskClub from a āholdā rating to a ābuyā rating in a research note issued on Friday, BidAskClub reports. Several other research firms have also recently weighed in on ANIK. Barrington Research cut shares of Anika Therapeutics from an āoutperformā rating to a āmarket performā rating in [ā¦]
- 07/05/2020
|
Anika Therapeutics (NASDAQ:ANIK) Stock Rating Lowered by Zacks Investment Research
- Anika Therapeutics (NASDAQ:ANIK) was downgraded by Zacks Investment Research from a āholdā rating to a āsellā rating in a research report issued to clients and investors on Monday, Zacks.com reports. According to Zacks, āAnika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of [ā¦]
- 06/24/2020
|
Hedge Funds Are Still Bullish On Anika Therapeutics, Inc. (ANIK)
- Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out [ā¦]
- 06/23/2020
|
Global Cartilage Repair/Regeneration Market Analysis and Forecasts to 2025, with Key Players Profiles Including Anika Therapeutics, Inc., Arthrex, Inc, DePuy Synthes and Zimmer Biomet - ResearchAndMarkets.com
|
Xconomy: Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More
- Race is not a topic that often comes up in pharmaceutical discussions but perhaps it should. Disease doesnāt discriminate by race, but health and economic
- 06/05/2020
|
Anika Announces Planned CFO Transition
- Anika Therapeutics, Inc. (ANIK), a global, integrated joint preservation and regenerative therapies company with products across the orthopedic early intervention continuum of care, today announced that Sylvia Cheung, Chief Financial Officer, has informed the Board of Directors of her decision, following a period of transition, to step away from her role at Anika effective August 21, 2020. āSylvia is an exemplary leader who has made many meaningful contributions to Anika over the years,ā said Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer of Anika.
- 06/02/2020
|
JETS Sees Asset Growth But Not Ready To Fly The Friendly Skies (NYSEARCA:JETS)
- Investors are betting on clear skies ahead for U.S. airlines with the U.S. Global JETS ETF (JETS) seeing a 3500% increase in assets in just three months. JETS i
- 05/21/2020
|
Anika to Participate in 2020 UBS Virtual Global Healthcare Conference
- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company, today announced that Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer, will present at the 2020 UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 8:20 a.m. ET.
- 05/12/2020
|
Anika to Participate in 2020 UBS Virtual Global Healthcare Conference
- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company, today announced that Cheryl R. Bl
- 05/12/2020
|
Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q1 2020 Results - Earnings Call Transcript
- Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2020 Results Earnings Conference Call May 07, 2020, 05:00 PM ET Company Participants Sylvia Cheung - Chief Financial O
- 05/09/2020
|
Anika Therapeutics Inc (ANIK) Q1 2020 Earnings Call Transcript
- With me on the call today is Dr. Cheryl Blanchard, who was recently appointed President and Chief Executive Officer of Anika. During today's call, Cheryl and I will review our first quarter 2020 financial results and key business highlights, which were summarized in our earnings release issued today.
- 05/09/2020
|
Anika (ANIK) Moves to Buy: Rationale Behind the Upgrade
- Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 05/08/2020
|
COVID-19 Impact and Recovery Analysis | Global Osteoarthritis Therapeutics Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Anika Therapeutics Inc. | Technavio
- The osteoarthritis therapeutics market size has the potential to grow by USD 2.99 billion during 2020-2024
- 05/08/2020
|
Anika Reports First Quarter 2020 Financial Results
- Total Revenue Increases 43% Year-over-YearContinued Progress on Integration of Parcus Medical and Arthrosurface AcquisitionsWithdrawing Full Year 2020 Financial Guidance Well.
- 05/07/2020
|
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
- 05/07/2020
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last weekĀ on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
Does Anika Therapeutics, Inc. (NASDAQ:ANIK) Have A High Beta?
- Anyone researching Anika Therapeutics, Inc. (NASDAQ:ANIK) might want to consider the historical volatility of the...
- 05/01/2020
|
Anika Therapeutics (ANIK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/30/2020
|
Anika Therapeutics (ANIK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/30/2020
|
Anika Therapeutics (ANIK) Set to Announce Quarterly Earnings on Thursday
- Anika Therapeutics (NASDAQ:ANIK) will be issuing its quarterly earnings data after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of $0.40 per share for the quarter. Anika Therapeutics has set its FY 2020 After-Hours guidance at EPS.Individual interested in listening to the companyās earnings conference call can do so [ā¦]
- 04/30/2020
|
Outlook on the Worldwide Wound Care Biologics Industry to 2025 - Extensive Profiles and Recent Developments of Market Players
- Dublin, April 30, 2020 -- The "Global Wound Care Biologics Market 2019-2025" report has been added to ResearchAndMarkets.com's offering. The global wound.
- 04/30/2020
|
BBVA USA Bancshares Inc. Has $515,000 Holdings in Anika Therapeutics Inc (NASDAQ:ANIK)
- BBVA USA Bancshares Inc. lifted its holdings in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 2.5% in the 1st quarter, Holdings Channel reports. The institutional investor owned 17,807 shares of the biotechnology companyās stock after acquiring an additional 437 shares during the period. BBVA USA Bancshares Inc.ās holdings in Anika Therapeutics were worth $515,000 at [ā¦]
- 04/30/2020
|
Zacks Investment Research Upgrades Anika Therapeutics (NASDAQ:ANIK) to "Buy"
- Anika Therapeutics (NASDAQ:ANIK) was upgraded by Zacks Investment Research from a āholdā rating to a ābuyā rating in a research note issued to investors on Monday, Zacks.com reports. The brokerage currently has a $37.00 price objective on the biotechnology companyās stock. Zacks Investment Researchās price target would indicate a potential upside of 11.41% from the [ā¦]
- 04/29/2020
|
Bank of America Corp DE Sells 6,906 Shares of Anika Therapeutics Inc (NASDAQ:ANIK)
- Bank of America Corp DE reduced its holdings in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 42.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 9,211 shares of the biotechnology companyās stock after selling 6,906 shares during the quarter. Bank of America Corp DEās holdings in Anika Therapeutics were worth $478,000 as of its [ā¦]
- 04/29/2020
|
ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?
- ANIK vs. ALKS: Which Stock Is the Better Value Option?
- 04/28/2020
|
ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?
- ANIK vs. ALKS: Which Stock Is the Better Value Option?
- 04/28/2020
|
Global Wound Care Biologics Market (2019 to 2025) - Featuring 3M, Acell & Anika Therapeutics Among Others - ResearchAndMarkets.com
- The "Global Wound Care Biologics Market 2019-2025" report has been added to ResearchAndMarkets.com's offering.
- 04/28/2020
|
BRIEF-Anika Names Cheryl R. Blanchard As President And CEO
- Anika Therapeutics Inc:
- 04/27/2020
|
Anika Therapeutics appoints Cheryl Blanchard, Ph.D. as CEO ANIK
- Anika Therapeutics appoints Cheryl Blanchard, Ph.D. as CEO ANIK
- 04/27/2020
|
Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer
- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced that Cheryl R. Blanchard, Ph.D., has been named President and Chief Executive Officer, effective April 26,2020. Dr. Blanchard has served as interim Chief Executive Officer of Anika since February 2020 and as a member of the Companyās Board of Directors since August 2018. Dr. Blanchard has more than 25 years of executive management experience with deep expertise in orthopedic medical devices, regenerative medicine and drug delivery.
- 04/27/2020
|
Boston Trust Walden Corp Acquires 106,501 Shares of Anika Therapeutics Inc (NASDAQ:ANIK)
- Boston Trust Walden Corp lifted its position in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 48.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 326,319 shares of the biotechnology companyās stock after acquiring an additional 106,501 shares during the quarter. Boston Trust Walden Corpās holdings in [ā¦]
- 04/27/2020
|
Merit Medical Systems (MMSI) Receives a Buy from Barrington
- In a report released today, Michael Petusky from Barrington maintained a Buy rating on Merit Medical Systems (MMSI), with a price target of $42.00. The
- 04/24/2020
|
Merit Medical Systems (MMSI) Receives a Buy from Barrington
- In a report released today, Michael Petusky from Barrington maintained a Buy rating on Merit Medical Systems (MMSI ā Research
- 04/24/2020
|
Anika to Issue First Quarter 2020 Financial Results and Business Highlights on Thursday, May 7
- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first quarter 2020 financial results after the close of the market on Thursday, May 7, 2020 and hold its investor conference call on the same day, Thursday, May 7, 2020, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook.
- 04/23/2020
|
Boston Trust Walden Corp Boosts Position in Anika Therapeutics Inc (NASDAQ:ANIK)
- Boston Trust Walden Corp boosted its holdings in Anika Therapeutics Inc (NASDAQ:ANIK) by 76.4% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 387,747 shares of the biotechnology companyās stock after buying an additional 167,929 shares during the period. Boston Trust Walden Corp owned approximately 2.74% of Anika [ā¦]
- 04/23/2020
|
Anika Therapeutics (NASDAQ:ANIK) Rating Increased to Buy at Zacks Investment Research
- Anika Therapeutics (NASDAQ:ANIK) was upgraded by Zacks Investment Research from a āholdā rating to a ābuyā rating in a report issued on Tuesday, Zacks.com reports. The brokerage presently has a $37.00 price objective on the biotechnology companyās stock. Zacks Investment Researchās target price indicates a potential upside of 17.95% from the companyās current price. According [ā¦]
- 04/23/2020
|
Anika Therapeutics (NASDAQ:ANIK) Lifted to "Hold" at BidaskClub
- Anika Therapeutics (NASDAQ:ANIK) was upgraded by equities research analysts at BidaskClub from a āsellā rating to a āholdā rating in a research report issued on Wednesday, BidAskClub reports. Other analysts also recently issued reports about the stock. Barrington Research reiterated a ābuyā rating and issued a $60.00 price objective on shares of Anika Therapeutics in [ā¦]
- 04/22/2020
|
Anika Therapeutics Inc (NASDAQ:ANIK) Shares Bought by Assenagon Asset Management S.A.
- Assenagon Asset Management S.A. raised its holdings in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 570.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 98,670 shares of the biotechnology companyās stock after acquiring an additional 83,948 shares during the period. [ā¦]
- 04/21/2020
|
Merit Medical Systems (MMSI) Gets a Hold Rating from Barrington
- Barrington analyst Michael Petusky maintained a Hold rating on Merit Medical Systems (MMSI) today. The company's shares closed last Friday at $37.61.
- 04/20/2020
|
Merit Medical Systems (MMSI) Gets a Hold Rating from Barrington
- Barrington analyst
Michael Petusky
maintained a
Hold
rating on Merit Medical Systems (
MMSI
ā
Research Report
) today. The companyās shares closed last Friday at $37.61.
According to
TipRanks.com
, Petusky is a 2-star analyst with an average return o
- 04/20/2020
|
Anika Therapeutics Inc (NASDAQ:ANIK) Shares Acquired by Geode Capital Management LLC
- Geode Capital Management LLC lifted its stake in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 1.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 222,854 shares of the biotechnology companyās stock after buying an additional 2,332 shares during the quarter. Geode Capital Management [ā¦]
- 04/20/2020
|
The Consensus EPS Estimates For Anika Therapeutics, Inc. (NASDAQ:ANIK) Just Fell Dramatically
- One thing we could say about the analysts on Anika Therapeutics, Inc. (NASDAQ:ANIK) - they aren't optimistic, having...
- 04/15/2020
|
Bank of New York Mellon Corp Has $11.61 Million Stake in Anika Therapeutics Inc (NASDAQ:ANIK)
- Bank of New York Mellon Corp trimmed its stake in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 4.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 223,931 shares of the biotechnology companyās stock after selling 11,095 shares during the period. Bank [ā¦]
- 04/10/2020
|
The Daily Biotech Pulse: FDA Nod For Pfizer, Vanda Forges Partnership For COVID-19 Drug Research, Neuronetics Pre-Announces Revenue Shortfall
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 8) * Keros Therapeutics Inc (NASDAQ: KROS) (went public Wednesday and traded 25.5% higher to $20.08, up from the IPO price of $16)None of the NYSE- or Nasdaq-listed
- 04/09/2020
|
Anika Therapeutics Inc (NASDAQ:ANIK) Receives $53.75 Average Price Target from Analysts
- Anika Therapeutics Inc (NASDAQ:ANIK) has been assigned a consensus recommendation of āHoldā from the eight research firms that are presently covering the firm, Marketbeat reports. Four analysts have rated the stock with a sell rating, two have given a buy rating and one has given a strong buy rating to the company. The average twelve-month [ā¦]
- 04/09/2020
|
Anika Therapeutics Inc (NASDAQ:ANIK) Shares Sold by Advisor Group Inc.
- Advisor Group Inc. trimmed its stake in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 46.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 522 shares of the biotechnology companyās stock after selling 450 shares during the quarter. Advisor Group Inc.ās holdings [ā¦]
- 04/09/2020
|
BRIEF-Anika Therapeutics Says Drawing Down $50 Mln On Existing Credit Facility
- Anika Therapeutics Inc:
- 04/08/2020
|
Anika Takes Actions to Strengthen Liquidity in Light of COVID-19
- Anika Therapeutics, Inc. (ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (āHAā) technology platform, today provided an update on actions it is taking to strengthen liquidity in light of the COVID-19 pandemic. To strengthen its financial position, the Company is drawing down $50 million on its existing credit facility. Following the drawdown, the Company will have total liquidity of approximately $140 million, comprised of cash and investments on hand.
- 04/08/2020
|
Anika Takes Actions to Strengthen Liquidity in Light of COVID-19
- BEDFORD, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative...
- 04/08/2020
|
Cubist Systematic Strategies LLC Boosts Stake in Anika Therapeutics Inc (NASDAQ:ANIK)
- Cubist Systematic Strategies LLC lifted its holdings in Anika Therapeutics Inc (NASDAQ:ANIK) by 143.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,104 shares of the biotechnology companyās stock after buying an additional 12,425 shares during the period. [ā¦]
- 04/05/2020
|
Stocksā Losses Grow After News of 701,000 Lost Jobs
- U.S.nonfarm payrolls shrank by 701,000 jobs in March. Economists had expected a loss of 100,000. Stocks are holding steady while oil prices are soaring.
- 04/03/2020
|
3 Benjamin Graham-Style Stocks
- These picks have a Graham blended multiplier below 22.5 Continue reading...
- 04/02/2020
|
3 Benjamin Graham-Style Stocks
- 3 Benjamin Graham-Style Stocks, Stocks: ENB,BGS,ANIK, release date:Apr 02, 2020
- 04/02/2020
|
Outlook on the Global Adhesion Barrier Industry to 2027 - Featuring Anika Therapeutics, Sanofi Group & PlantTec Medical Among Others
- Dublin, April 02, 2020 -- The "Adhesion Barrier - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering. The.
- 04/02/2020
|
Anika Therapeutics (NASDAQ:ANIK) Upgraded to "Sell" at ValuEngine
- Anika Therapeutics (NASDAQ:ANIK) was upgraded by equities research analysts at ValuEngine from a āstrong sellā rating to a āsellā rating in a report released on Thursday, ValuEngine reports. Several other research firms have also issued reports on ANIK. Sidoti upgraded Anika Therapeutics from a āneutralā rating to a ābuyā rating and set a $61.00 target [ā¦]
- 04/02/2020
|
AQR Capital Management LLC Boosts Position in Anika Therapeutics Inc (NASDAQ:ANIK)
- AQR Capital Management LLC boosted its holdings in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 154.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 90,079 shares of the biotechnology companyās stock after buying an additional 54,668 shares during the quarter. AQR Capital Management LLC [ā¦]
- 04/01/2020
|
What Is Anika Therapeuticsās (NASDAQ:ANIK) P/E Ratio After Its Share Price Tanked?
- Unfortunately for some shareholders, the Anika Therapeutics (NASDAQ:ANIK) share price has dived 32% in the last thirty...
- 03/31/2020
|
Anika Therapeutics Inc (NASDAQ:ANIK) Holdings Decreased by Baird Financial Group Inc.
- Baird Financial Group Inc. reduced its stake in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 1.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 176,375 shares of the biotechnology companyās stock after selling 2,038 shares during the quarter. Baird Financial [ā¦]
- 03/27/2020
|
How Does Anika Therapeutics's (NASDAQ:ANIK) P/E Compare To Its Industry, After The Share Price Drop?
- To the annoyance of some shareholders, Anika Therapeutics (NASDAQ:ANIK) shares are down a considerable 32% in the last...
- 03/26/2020
|
Anika Therapeutics Inc (NASDAQ:ANIK) Shares Acquired by Bank of Montreal Can
- Bank of Montreal Can lifted its stake in Anika Therapeutics Inc (NASDAQ:ANIK) by 31.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,801 shares of the biotechnology companyās stock after buying an additional 429 shares during the period. Bank of Montreal Canās [ā¦]
- 03/26/2020
|
Envestnet Asset Management Inc. Boosts Stock Holdings in Anika Therapeutics Inc (NASDAQ:ANIK)
- Envestnet Asset Management Inc. raised its holdings in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 11.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 19,351 shares of the biotechnology companyās stock after acquiring an additional 1,979 shares during the period. Envestnet Asset Management Inc.ās holdings in Anika Therapeutics were worth $1,003,000 at the [ā¦]
- 03/24/2020
|
Great West Life Assurance Co. Can Makes New $869,000 Investment in Anika Therapeutics Inc (NASDAQ:ANIK)
- Great West Life Assurance Co. Can acquired a new position in shares of Anika Therapeutics Inc (NASDAQ:ANIK) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,910 shares of the biotechnology companyās stock, valued at approximately $869,000. Great West [ā¦]
- 03/23/2020
|
Anika Therapeutics (NASDAQ:ANIK) Downgraded by BidaskClub to Strong Sell
- BidaskClub cut shares of Anika Therapeutics (NASDAQ:ANIK) from a sell rating to a strong sell rating in a report issued on Tuesday, BidAskClub reports. Several other equities analysts have also recently weighed in on ANIK. ValuEngine cut shares of Anika Therapeutics from a sell rating to a strong sell rating in a research report on [ā¦]
- 03/21/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (NASDAQ: CNTG) * Gilead Sciences, Inc. (NASDAQ: GILD) * Imara Inc (NASDAQ: IMRA) * Regeneron Pharmaceuticals
- 03/20/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
- 03/20/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
Worldwide Arthralgia (Joint Pain) Clinical Trials Insights, 2020 by Trial Status, Trial Phase, Sponsor Type, End Point Status, Region and Country
- The "Arthralgia (Joint Pain) Clinical Trials Review H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
- 03/18/2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) ( Updated on its COVID-19 treatment development plan)Down In The
- 03/18/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
What Is Anika Therapeuticsās (NASDAQ:ANIK) P/E Ratio After Its Share Price Tanked?
- Unfortunately for some shareholders, the Anika Therapeutics (NASDAQ:ANIK) share price has dived 35% in the last thirty...
- 03/17/2020
|
Arthralgia (Joint Pain) Global Clinical Trials Review H1, 2020
- Dublin, March 17, 2020 -- The "Arthralgia (Joint Pain) Global Clinical Trials Review H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering..
- 03/17/2020
|
Brokerages Set Anika Therapeutics Inc (NASDAQ:ANIK) PT at $53.75
- Shares of Anika Therapeutics Inc (NASDAQ:ANIK) have earned an average rating of āHoldā from the eight ratings firms that are presently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a sell rating, two have given a buy rating and one has issued a strong buy rating on the company. [ā¦]
- 03/15/2020
|
Anika Therapeutics (NASDAQ:ANIK) Sets New 12-Month Low at $27.49
- Shares of Anika Therapeutics Inc (NASDAQ:ANIK) reached a new 52-week low on Friday . The stock traded as low as $27.49 and last traded at $31.00, with a volume of 21516 shares traded. The stock had previously closed at $30.27. Several research analysts recently weighed in on the stock. First Analysis upgraded shares of Anika [ā¦]
- 03/15/2020
|
Financial Contrast: Anika Therapeutics (NASDAQ:ANIK) and Inovio Pharmaceuticals (NASDAQ:INO)
- Anika Therapeutics (NASDAQ:ANIK) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk. Valuation & Earnings This table compares Anika Therapeutics and Inovio Pharmaceuticalsā top-line revenue, earnings per [ā¦]
- 03/13/2020
|
Viscosupplementation Market Forecast to 2027; Analyzed by Product (Single, Three, Five Injection) and End-use (Hospitals, Orthopedic Clinics/ASCs)
- The "Viscosupplementation Market Size, Share & Trends Analysis Report by Product (Single Injection, Three Injection, Five Injection), by End-use (Hospitals, Orthopedic Clinics/ASCs), and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
- 03/12/2020
|
Charles Schwab Investment Management Inc. Grows Stock Position in Anika Therapeutics Inc (NASDAQ:ANIK)
- Charles Schwab Investment Management Inc. increased its position in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 2.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 120,966 shares of the biotechnology companyās stock after buying an additional 3,179 shares during the quarter. Charles Schwab [ā¦]
- 03/12/2020
|
Can You Imagine How Anika Therapeutics's (NASDAQ:ANIK) Shareholders Feel About The 29% Share Price Increase?
- Anika Therapeutics, Inc. (NASDAQ:ANIK) shareholders might be concerned after seeing the share price drop 29% in the...
- 03/11/2020
|
Anika Therapeutics Inc (NASDAQ:ANIK) Stock Holdings Increased by Ajo LP
- Ajo LP raised its holdings in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 0.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 190,261 shares of the biotechnology companyās stock after acquiring an additional 1,720 shares during the period. Ajo LP owned [ā¦]
- 03/11/2020
|
Clinical Study Shows Improved Clinical Outcomes, High Rate of Return to Activity for Patients with Arthrosurface OVO with Inlay Glenoid Shoulder Arthroplasty System
- A new study published in the Journal of Shoulder and Elbow Surgery found that younger, active adults who underwent anatomic total shoulder arthroplasty (TSA) and received the OVOĀ® with Inlay Glenoid Shoulder Arthroplasty System experienced excellent range of motion, improved clinical outcomes, no reoperations
- 03/10/2020
|
Varian Medical Systems (VAR) Gets a Buy Rating from Barrington
- Barrington analyst Michael Petusky maintained a Buy rating on Varian Medical Systems (VAR) today and set a price target of $147.00. The company's shares
- 03/10/2020
|
Global Viscosupplementation Markets, 2020-2027 - Key Players are Anika Therapeutics, Sanofi, Ferring, Seikagaku, Bioventus, Zimmer Holdings, LG Life Sciences, and Lifecore Biomedical
- Dublin, March 10, 2020 -- The "Viscosupplementation Market Size, Share & Trends Analysis Report by Product (Single Injection, Three Injection, Five Injection), by.
- 03/10/2020
|
KBC Group NV Increases Position in Anika Therapeutics Inc (NASDAQ:ANIK)
- KBC Group NV raised its position in Anika Therapeutics Inc (NASDAQ:ANIK) by 82.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,131 shares of the biotechnology companyās stock after purchasing an additional 12,266 shares during the quarter. KBC Group NV owned [ā¦]
- 03/09/2020
|
Barclays PLC Decreases Stock Holdings in Anika Therapeutics Inc (NASDAQ:ANIK)
- Barclays PLC trimmed its holdings in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 20.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,833 shares of the biotechnology companyās stock after selling 7,332 shares during the quarter. Barclays PLC owned 0.20% of Anika Therapeutics worth [ā¦]
- 03/09/2020
|
Anika Therapeutics Inc (NASDAQ:ANIK) Shares Sold by New York State Common Retirement Fund
- New York State Common Retirement Fund decreased its stake in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 12.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,100 shares of the biotechnology companyās stock after selling 1,800 shares during the period. New York State Common Retirement [ā¦]
- 03/07/2020
|
Comerica Bank Has $575,000 Stock Holdings in Anika Therapeutics Inc (NASDAQ:ANIK)
- Comerica Bank raised its holdings in Anika Therapeutics Inc (NASDAQ:ANIK) by 3.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,392 shares of the biotechnology companyās stock after purchasing an additional 469 shares during the quarter. Comerica Bankās holdings in Anika Therapeutics [ā¦]
- 03/06/2020
|
Edited Transcript of ANIK.OQ earnings conference call or presentation 20-Feb-20 10:00pm GMT
- Q4 2019 Anika Therapeutics Inc Earnings Call
- 03/05/2020
|
Anika Therapeutics appoints David Colleran general counsel ANIK;PODD
- Anika Therapeutics appoints David Colleran general counsel ANIK PODD
- 03/04/2020
|
Anika Appoints David Colleran as General Counsel
- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced the appointment of David Colleran to the newly created position of Executive Vice President, General Counsel and Corporate Secretary. In this new role, Mr. Colleran will lead the Companyās global legal organization, including corporate governance and compliance.
- 03/04/2020
|
Have Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Been Selling Their Stock?
- Anyone interested in Anika Therapeutics, Inc. (NASDAQ:ANIK) should probably be aware that the Independent Director...
- 03/02/2020
|
Anika Therapeutics Inc (NASDAQ:ANIK) Director Sells $115,236.00 in Stock
- Anika Therapeutics Inc (NASDAQ:ANIK) Director Raymond J. Land sold 2,700 shares of the firmās stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $42.68, for a total transaction of $115,236.00. Following the completion of the sale, the director now directly owns 16,099 shares in the company, valued [ā¦]
- 02/29/2020
|
Los Angeles Capital Management & Equity Research Inc. Grows Stake in Anika Therapeutics Inc (NASDAQ:ANIK)
- Los Angeles Capital Management & Equity Research Inc. increased its stake in Anika Therapeutics Inc (NASDAQ:ANIK) by 15.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,497 shares of the biotechnology companyās stock after acquiring an additional 1,030 [ā¦]
- 02/29/2020
|
Research Analysts Offer Predictions for Anika Therapeutics Inc's FY2020 Earnings (NASDAQ:ANIK)
- Anika Therapeutics Inc (NASDAQ:ANIK) ā Equities researchers at BWS Financial issued their FY2020 earnings per share estimates for Anika Therapeutics in a report released on Monday, February 24th. BWS Financial analyst H. Khorsand forecasts that the biotechnology company will post earnings of $0.49 per share for the year. BWS Financial currently has a āSellā rating [ā¦]
- 02/29/2020
|
Reviewing Encision (OTCMKTS:ECIA) and Anika Therapeutics (OTCMKTS:ANIK)
- Encision (OTCMKTS:ECIA) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Risk and Volatility Encision has a beta of -0.52, suggesting that its share price is 152% [ā¦]
- 02/29/2020
|
Hyaluronic Acid Market To Reach USD 15.48 Billion By 2027 | Reports And Data
- New York, Feb. 27, 2020 -- The globalĀ Hyaluronic Acid marketĀ is expected to reach USD 15.48 Billion by 2027, according to a new report by Reports and Data. The growth of the.
- 02/27/2020
|
New Strong Sell Stocks for February 27th
- Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
- 02/27/2020
|
New Strong Sell Stocks for February 27th
- Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
- 02/27/2020
|
Hyaluronic Acid Market Size, Share & Trends Analysis Report By Application,, By Region And Segment Forecasts, 2020 - 2027
- New York, Feb. 27, 2020 -- Reportlinker.com announces the release of the report "Hyaluronic Acid Market Size, Share & Trends Analysis Report By Application,, By Region And.
- 02/27/2020
|
$16.6 Billion Hyaluronic Acid Market Insights, 2027 Featuring Roche, Seikagaku, Galderma, Sanofi, Anika Therapeutics, Salix Pharma, Zimmer, Allergan, Ferring Pharma, Smith & Nephew, and More
- /PRNewswire/ -- The "Hyaluronic Acid Market Size, Share & Trends Analysis Report By Application (Dermal Fillers, Osteoarthritis (Single Injection, Three...
- 02/26/2020
|
Hyaluronic Acid Market to Rapidly Expand at a CAGR of 8.1% Between 2020 & 2027 - Growing Applications in Regenerative Medicine & Tissue Engineering is a Key Driver
- Dublin, Feb. 26, 2020 -- The "Hyaluronic Acid Market Size, Share & Trends Analysis Report By Application (Dermal Fillers, Osteoarthritis (Single Injection, Three.
- 02/26/2020
|
Anika Therapeutics (NASDAQ:ANIK) Rating Lowered to Sell at Zacks Investment Research
- Anika Therapeutics (NASDAQ:ANIK) was downgraded by Zacks Investment Research from a āholdā rating to a āsellā rating in a research report issued on Monday, Zacks.com reports. According to Zacks, āAnika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic [ā¦]
- 02/26/2020
|
Anika Therapeutics (NASDAQ:ANIK) Upgraded by BidaskClub to "Sell"
- Anika Therapeutics (NASDAQ:ANIK) was upgraded by equities research analysts at BidaskClub from a āstrong sellā rating to a āsellā rating in a note issued to investors on Wednesday, BidAskClub reports. ANIK has been the subject of a number of other research reports. TheStreet downgraded Anika Therapeutics from a ābā rating to a āc+ā rating in [ā¦]
- 02/26/2020
|
Analysts Offer Insights on Healthcare Companies: Endologix (ELGX) and Merit Medical Systems (MMSI)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Endologix (ELGX) and Merit Medical Systems (MMSI). Endologix (ELGX) BTIG
- 02/25/2020
|
Analysts Offer Insights on Healthcare Companies: Endologix (NASDAQ: ELGX) and Merit Medical Systems (NASDAQ: MMSI)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Endologix (
ELGX
ā
Research Report
) and Merit Medical Systems (
MMSI
ā
Research Report
).
Endologix (ELGX)
BTIG analyst
Marie Thibault
maintained a
Buy
rating on Endol
- 02/25/2020
|
Anika Therapeutics (NASDAQ:ANIK) Downgraded by ValuEngine to "Strong Sell"
- Anika Therapeutics (NASDAQ:ANIK) was downgraded by stock analysts at ValuEngine from a āsellā rating to a āstrong sellā rating in a research report issued to clients and investors on Tuesday, ValuEngine reports. ANIK has been the subject of several other research reports. Zacks Investment Research cut shares of Anika Therapeutics from a āholdā rating to [ā¦]
- 02/25/2020
|
A Look At The Fair Value Of Anika Therapeutics, Inc. (NASDAQ:ANIK)
- In this article we are going to estimate the intrinsic value of Anika Therapeutics, Inc. (NASDAQ:ANIK) by estimating...
- 02/24/2020
|
First Analysis Analysts Reduce Earnings Estimates for Anika Therapeutics Inc (NASDAQ:ANIK)
- Anika Therapeutics Inc (NASDAQ:ANIK) ā Equities research analysts at First Analysis dropped their Q2 2020 EPS estimates for Anika Therapeutics in a research report issued on Friday, February 21st. First Analysis analyst J. Munda now expects that the biotechnology company will post earnings per share of $0.53 for the quarter, down from their previous forecast [ā¦]
- 02/24/2020
|
Anika Therapeutics Beats Revenue and Earnings Estimates
- A recent acquisition and a new product launch held back earnings, but should be beneficial over the long term.
- 02/21/2020
|
Barrington Research Reiterates Buy Rating for Anika Therapeutics (NASDAQ:ANIK)
- Anika Therapeutics (NASDAQ:ANIK)ās stock had its ābuyā rating reaffirmed by investment analysts at Barrington Research in a research report issued to clients and investors on Friday, AnalystRatings.com reports. They currently have a $60.00 price target on the biotechnology companyās stock. Barrington Researchās target price points to a potential upside of 39.63% from the companyās previous [ā¦]
- 02/21/2020
|
Barrington Maintains a Buy Rating on Anika Therapeutics (ANIK)
- In a report released today, Michael Petusky from Barrington maintained a Buy rating on Anika Therapeutics (ANIK), with a price target of $60.00. The
- 02/21/2020
|
Barrington Maintains a Buy Rating on Anika Therapeutics (ANIK)
- In a report released today,
Michael Petusky
from Barrington maintained a
Buy
rating on Anika Therapeutics (
ANIK
ā
Research Report
), with a price target of
$60.00
. The companyās shares closed last Monday at $44.96.
According to
TipRanks.com
, Petus
- 02/21/2020
|
Global Outlook on the Viscosupplementation Market to 2025 - Based on Product Type, Procedure Type, Injection Cycle, and Application - ResearchAndMarkets.com
- The "Viscosupplementation: Global Market Overview" report has been added to ResearchAndMarkets.com's offering.
- 02/21/2020
|
The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...
- 02/21/2020
|
Anika Therapeutics Inc (ANIK) Q4 2019 Earnings Call Transcript
- ANIK earnings call for the period ending December 31, 2019.
- 02/21/2020
|
Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q4 2019 Results - Earnings Call Transcript
- Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2019 Earnings Conference Call February 20, 2020, 17:00 ET Company Participants Sylvia Cheung - CFO, Treasurer & Se
- 02/21/2020
|
Anika Therapeutics (ANIK) Beats Q4 Earnings and Revenue Estimates
- Anika (ANIK) delivered earnings and revenue surprises of 4.88% and 7.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- 02/21/2020
|
Anika Therapeutics (ANIK) Beats Q4 Earnings and Revenue Estimates
- Anika (ANIK) delivered earnings and revenue surprises of 4.88% and 7.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- 02/21/2020
|
Anika: 4Q Earnings Snapshot
- BEDFORD, Mass. (AP) _ Anika Therapeutics Inc. (ANIK) on Thursday reported fourth-quarter net income of $4.1 million. The Bedford, Massachusetts-based company said it had profit of 28 cents per share. Earnings, adjusted for costs related to mergers and acquisitions, were 43 cents per share. The medical technology company posted revenue of $29.8 million in the period. For the year, the company reported profit of $27.2 million, or $1.89 per share. Revenue was reported as $114.5 million. Anika expects full-year revenue in the range of $160 million to $165 million. Anika shares have dropped 19% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $42, a rise of almost 5% in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ANIK at https://www.zacks.com/ap/ANIK
- 02/20/2020
|
Anika: 4Q Earnings Snapshot
- BEDFORD, Mass. (AP) _ Anika Therapeutics Inc. (ANIK) on Thursday reported fourth-quarter net income of $4.1 million.
The Bedford, Massachusetts-based company said it had profit of 28 cents per share. Earnings, adjusted for costs related to mergers an
- 02/20/2020
|
BRIEF-Anika Reports Q4 Earnings Per Share $0.28
- Anika Therapeutics Inc:
- 02/20/2020
|
Anika Reports Fourth Quarter and Full Year 2019 Financial Results
- Total Revenue Increases 10% Year-over-Year for the Fourth QuarterCompletes Acquisitions of Parcus Medical and ArthrosurfaceCompany Expects Total Revenue Growth in the 40% to 44%.
- 02/20/2020
|
The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia ...
- 02/20/2020
|
The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 18) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Anavex ...
- 02/19/2020
|
2020 Viscosupplementation Industry Report - Featuring Profiles of Anika Therapeutics, Bioventus, Chugai Pharma, Sanofi, Seikagaku, and More
- /PRNewswire/ -- The "Viscosupplementation: Global Market Overview" report has been added to ResearchAndMarkets.com's offering. The global viscosupplementation...
- 02/18/2020
|
Global Viscosupplementation Market Overview 2020
- Dublin, Feb. 18, 2020 -- The "Viscosupplementation: Global Market Overview" report has been added to ResearchAndMarkets.com's offering. The global.
- 02/18/2020
|
Viscosupplementation: Global Market Overview
- Report Scope: The current report offers a detailed picture of the viscosupplementation market. Viscosupplementation is indicated for the treatment of knee, hip, shoulder and ankle osteoarthritis. Hyaluronic acid viscosupplement is injected into joints to reduce joint pains and treat osteoarthritis.
- 02/17/2020
|
Anika Therapeutics Inc (NASDAQ:ANIK) Receives Average Rating of "Hold" from Analysts
- Anika Therapeutics Inc (NASDAQ:ANIK) has earned a consensus rating of āHoldā from the nine ratings firms that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating [ā¦]
- 02/16/2020
|
The Week Ahead In Biotech: Agile, Baudax Bio, Merck and Esperion Await FDA Decisions
- Biotech stocks were quiet in the week endingĀ Feb. 14 amid some data readouts at a couple of conferences and earnings news flow from smid-cap companies. The following areĀ key biotech catalysts to look forward ...
- 02/16/2020
|
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolutionās IPO & More
- Drugs typically go through three phases of clinical testing to support an application for FDA approval. Itās easy to overlook Phase 4, which takes place
- 02/14/2020
|
Analysts Estimate Anika Therapeutics (ANIK) to Report a Decline in Earnings: What to Look Out for
- Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/13/2020
|
Analysts Estimate Anika Therapeutics (ANIK) to Report a Decline in Earnings: What to Look Out for
- Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/13/2020
|
BRIEF-Anika Therapeutics Names Dr. Cheryl Blanchard As Interim CEO
- Anika Therapeutics Inc:
- 02/12/2020
|
Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO
- Anika Therapeutics, Inc. (ANIK) today announced that Dr. Cheryl Blanchard, a member of the Companyās Board of Directors since August 2018, has been named interim Chief Executive Officer, effective immediately, while the Board continues its search to identify a new CEO following the recent passing of Joseph Darling. In connection with Dr. Blanchardās appointment, the previously announced interim Office of the President has been dissolved. āWe are pleased that Dr. Blanchard, a seasoned executive who has previously served as a biotech President and CEO, has agreed to step in as our interim CEO as we search for Anikaās next leader,ā said Dr. Joseph Bower, Chairman of Anika's Board of Directors.
- 02/12/2020
|
Hyaluronic Acid-Based Dermal Fillers Market Size Worth $5.9 Billion by 2026: Grand View Research, Inc.
- The global hyaluronic acid-based dermal fillers market size is expected to reach USD 5.9 billion by 2026, based on a new report by Grand View Research, Inc., registering a 7.4% CAGR during the forecast period. Rising emphasis on physical appearances, increasing demand from the aging population to look
- 02/12/2020
|
Hyaluronic Acid Products Market - Global Industry Analysis and Opportunity Assessment, 2019-2029
- A recent market study published on the hyaluronic acid products market includes global industry analysis for 2014-2018 & opportunity assessment for 2019-2029, and delivers a comprehensive assessment of the most important market dynamics. After conducting a thorough research on the historical as well
- 02/07/2020
|
CORRECTING and REPLACING Anika to Issue Fourth-Quarter and Full-Year 2019 Financial Results and Business Highlights on Thursday, February 20
- First paragraph, first sentence should read: Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter and full-year 2019 financial results after the close of the market on Thursday, February 20, 2020 and hold its investor conference call on the same day, Thursday, February 20, 2020, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook.
- 02/06/2020
|
Anika to Issue Fourth-Quarter and Full-Year 2019 Financial Results and Business Highlights on Thursday, February 20
- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter and full-year 2019 financial results after
- 02/06/2020
|
How Does Anika Therapeutics, Inc. (NASDAQ:ANIK) Affect Your Portfolio Volatility?
- If you own shares in Anika Therapeutics, Inc. (NASDAQ:ANIK) then it's worth thinking about how it contributes to the...
- 02/06/2020
|
Dermal Fillers Market Value to Hit US $10.4B by 2026: Global Market Insights, Inc.
- The dermal fillers market demand in dermatological clinics is forecast to expand at a 7.7% CAGR over 2020 to 2026, owing to increasing dermatological clinics in emerging countries that are expanding their service offerings by addition of filler treatments, along with the shorter duration of cosmetic procedures and accessibility.
- 02/06/2020
|
Global Collagen and HA-based Biomaterials Markets, 2017-2027
- The "Collagen and HA-based Biomaterials Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
- 02/04/2020
|
Do You Like Anika Therapeutics, Inc. (NASDAQ:ANIK) At This P/E Ratio?
- This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
- 02/04/2020
|
Anika Therapeutics Closes Acquisition of Arthrosurface
- Anika Therapeutics, Inc.Ā (ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietaryĀ hyaluronic acid (HA) technology platform, today announced it has completed its acquisition of Arthrosurface, a leading, privately-held provider of joint surface and preservation solutions for active patients. Under the previously disclosed terms of the agreement, Anika acquired all outstanding shares of Arthrosurface in exchange for an upfront payment of approximatelyĀ $60 millionĀ in cash from the companyās existing balance sheet, subject to customary closing adjustments. Arthrosurface shareholders will be eligible to receive an additionalĀ $40 millionĀ contingent upon the achievement of certain regulatory and commercial milestones.
- 02/03/2020
|
Anika Therapeutics Closes Acquisition of Arthrosurface
- Transaction Accelerates Anikaās Revenue Growth, Broadens Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities and Expands Pipeline
- 02/03/2020
|
